242 related articles for article (PubMed ID: 22234678)
1. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Scott BL; Gooley TA; Sorror ML; Rezvani AR; Linenberger ML; Grim J; Sandmaier BM; Myerson D; Chauncey TR; Storb R; Buxhofer-Ausch V; Radich JP; Appelbaum FR; Deeg HJ
Blood; 2012 Mar; 119(11):2657-64. PubMed ID: 22234678
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
[TBL] [Abstract][Full Text] [Related]
3. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
[TBL] [Abstract][Full Text] [Related]
4. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Pereira A; Guglielmelli P; Pungolino E; Caramella M; Maffioli M; Pascutto C; Lazzarino M; Cazzola M; Tefferi A
Blood; 2010 Mar; 115(9):1703-8. PubMed ID: 20008785
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
7. Survival following allogeneic transplant in patients with myelofibrosis.
Gowin K; Ballen K; Ahn KW; Hu ZH; Ali H; Arcasoy MO; Devlin R; Coakley M; Gerds AT; Green M; Gupta V; Hobbs G; Jain T; Kandarpa M; Komrokji R; Kuykendall AT; Luber K; Masarova L; Michaelis LC; Patches S; Pariser AC; Rampal R; Stein B; Talpaz M; Verstovsek S; Wadleigh M; Agrawal V; Aljurf M; Angel Diaz M; Avalos BR; Bacher U; Bashey A; Beitinjaneh AM; Cerny J; Chhabra S; Copelan E; Cutler CS; DeFilipp Z; Gadalla SM; Ganguly S; Grunwald MR; Hashmi SK; Kharfan-Dabaja MA; Kindwall-Keller T; Kröger N; Lazarus HM; Liesveld JL; Litzow MR; Marks DI; Nathan S; Nishihori T; Olsson RF; Pawarode A; Rowe JM; Savani BN; Savoie ML; Seo S; Solh M; Tamari R; Verdonck LF; Yared JA; Alyea E; Popat U; Sobecks R; Scott BL; Nakamura R; Mesa R; Saber W
Blood Adv; 2020 May; 4(9):1965-1973. PubMed ID: 32384540
[TBL] [Abstract][Full Text] [Related]
8. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
9. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Gangat N; Caramazza D; Vaidya R; George G; Begna K; Schwager S; Van Dyke D; Hanson C; Wu W; Pardanani A; Cervantes F; Passamonti F; Tefferi A
J Clin Oncol; 2011 Feb; 29(4):392-7. PubMed ID: 21149668
[TBL] [Abstract][Full Text] [Related]
10. Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation.
Stevens EA; Jenkins IC; Beppu LW; Zhang Q; Salit R; Loeb KR; Deeg HJ; Radich JP
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1371-1374. PubMed ID: 32194289
[TBL] [Abstract][Full Text] [Related]
11. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.
Tefferi A; Partain DK; Palmer JM; Slack JL; Roy V; Hogan WJ; Litzow ML; Ketterling RP; Patnaik MM
Am J Hematol; 2018 May; 93(5):649-654. PubMed ID: 29388258
[TBL] [Abstract][Full Text] [Related]
13. Prognostic risk models for transplant decision-making in myelofibrosis.
Hernández-Boluda JC; Pereira A; Correa JG; Alvarez-Larrán A; Ferrer-Marín F; Raya JM; Martínez-López J; Velez P; Pérez-Encinas M; Estrada N; García-Gutiérrez V; Fox ML; Payer A; Kerguelen A; Cuevas B; Durán MA; Ramírez MJ; Gómez-Casares MT; Mata-Vázquez MI; Mora E; Gómez M; Cervantes F
Ann Hematol; 2018 May; 97(5):813-820. PubMed ID: 29396714
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
[TBL] [Abstract][Full Text] [Related]
15. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Patriarca F; Masciulli A; Bacigalupo A; Bregante S; Pavoni C; Finazzi MC; Bosi A; Russo D; Narni F; Messina G; Alessandrino EP; Carella AM; Milone G; Bruno B; Mammoliti S; Bruno B; Fanin R; Bonifazi F; Rambaldi A;
Biol Blood Marrow Transplant; 2019 May; 25(5):932-940. PubMed ID: 30579966
[TBL] [Abstract][Full Text] [Related]
16. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
[TBL] [Abstract][Full Text] [Related]
17. One thousand patients with primary myelofibrosis: the mayo clinic experience.
Tefferi A; Lasho TL; Jimma T; Finke CM; Gangat N; Vaidya R; Begna KH; Al-Kali A; Ketterling RP; Hanson CA; Pardanani A
Mayo Clin Proc; 2012 Jan; 87(1):25-33. PubMed ID: 22212965
[TBL] [Abstract][Full Text] [Related]
18. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
[TBL] [Abstract][Full Text] [Related]
19. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC; Pereira A; Kröger N; Beelen D; Robin M; Bornhäuser M; Angelucci E; Vitek A; Blau IW; Niittyvuopio R; Finke J; Cornelissen JJ; Passweg J; Dreger P; Petersen E; Kanz L; Sanz J; Zuckerman T; Zinger N; Iacobelli S; Hayden P; Czerw T; McLornan D; Yakoub-Agha I
Leukemia; 2021 Jan; 35(1):215-224. PubMed ID: 32286544
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
